Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Wavefront technology approval

This article was originally published in The Gray Sheet

Executive Summary

Shipments of Zywave II and Orbscann IIz eye diagnostic systems begin immediately upon PMA supplemental approval of the Zypotix personalised LASIK system, announced Oct. 10, building on Bausch & Lomb's Technolas 217z excimer laser platform. B&L will launch a series of TV ads for the system, approved to treat myopia up to -7 diopters and astigmatism up to -3 D (1"The Gray Sheet" Sept. 15, 2003, p. 9). Competitors include Visx and Alcon...

You may also be interested in...

B&L Looks To TV, Equipment Financing To Spur Zyoptix Wavefront LASIK Use

Bausch & Lomb will launch a TV ad campaign for the Zyoptix custom wavefront ablation system upon FDA approval by year-end, Senior VP and CFO Stephen McCluski said at the Bear Stearns annual healthcare conference in New York Sept. 9

APACMed 2020: Healthineers Evolves Therapy Remit And Makes All Asia An Equal Priority

Siemens Healthineers' product mix of diagnostics and imaging products meant it was in the middle of a very dynamic situation when COVID-19 struck.

WHO No-Go Not A Swan Song For Remdesivir In India?

The WHO’s new "living guideline" against remdesivir’s use in hospitalized patients notwithstanding, some key opinion leaders in India see a role for the antiviral, but underscore that COVID-19 is still in its infancy and all repurposed therapies for the disease still have a long way to go. They also see the US remdesivir studies as more robust.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts